Targeting lipid peroxidation and mitochondrial imbalance in Friedreich's ataxia

Pharmacological Research

Volumn 99, Issue , 2015, Pages 344-350

  Abeti, Rosella ^a   Uzun, Ebru ^a   Renganathan, Indhushri ^a   Honda, Tadashi ^b   Pook, Mark A ^c   Giunti, Paola ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b STONY BROOK UNIVERSITY   (United States)

^c BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

Friedreich's ataxia; Lipid peroxidation; Mitochondria; Nuclear factor E2 related factor; Oxidative stress; Poly unsaturated fatty acids

Indexed keywords

FRATAXIN; POLYUNSATURATED FATTY ACID; TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT; IRON; IRON BINDING PROTEIN; PHENANTHRENE DERIVATIVE; TBE 31;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY BALANCE; FIBROBLAST; FRIEDREICH ATAXIA; IMMUNOCYTOCHEMISTRY; LIPID PEROXIDATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; ANIMAL; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MITOCHONDRION; PATHOLOGY; PHENOTYPE; PHYSIOLOGY;

ANIMALS; ANTIOXIDANTS; CELL DEATH; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FIBROBLASTS; FRIEDREICH ATAXIA; IRON; IRON-BINDING PROTEINS; LIPID PEROXIDATION; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED C57BL; MITOCHONDRIA; OXIDATIVE STRESS; PHENANTHRENES; PHENOTYPE;

EID: 84938099619     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.05.015     Document Type: Article

References (37)

1. S. Al-Mahdawi, R.M. Pinto, P. Ruddle, C. Carroll, Z. Webster, and M. Pook GAA repeat instability in Friedreich ataxia YAC transgenic mice Genomics 84 2004 301 310
2. S. Al-Mahdawi, R.M. Pinto, D. Varshney, L. Lawrence, M.B. Lowrie, S. Hughes, and et al. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology Genomics 88 2006 580 590
3. P.R. Angelova, M.H. Horrocks, D. Klenerman, S. Gandhi, A.Y. Abramov, and M.S. Shchepinov Lipid peroxidation is essential for α-synuclein-induced cell death J Neurochem January 2015 10.1111/jnc.13024
4. A.-L. Bulteau, H.A. O'Neill, M.C. Kennedy, M. Ikeda-Saito, G. Isaya, and L.I. Szweda Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity Science (New York, N.Y.) 305 5681 2004 242 245 10.1126/science.1098991
5. K.J. Barnham, C.L. Masters, and A.I. Bush Neurodegenerative diseases and oxidative stress Nat Rev Drug Discov 3 3 2004 205 214 10.1038/nrd1330
6. M. Campanella, E. Casswell, S. Chong, Z. Farah, M.R. Wieckowski, A.Y. Abramov, and et al. Regulation of mitochondrial structure and function by the F1Fo-ATPase inhibitor protein, IF1 Cell Metab 8 July (1) 2008 13 25 10.1016/j.cmet.2008.06.001
7. M. Cossée, H. Puccio, A. Gansmuller, H. Koutnikova, A. Dierich, M. LeMeur, and et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation Hum Mol Genet 9 May (8) 2000 1219 1226
8. M.B. Delatycki, and L.A. Corben Clinical features of Friedreich ataxia J Child Neurol 27 9 2012 1133 1137 10.1177/0883073812448230
9. M.R. Duchen, A. Surin, and J. Jacobson Imaging mitochondrial function in intact cells Methods Enzymol. 361 2003 353 389
10. S. Goncalves, V. Paupe, E.P. Dassa, and P. Rustin Deferiprone targets aconitase: implication for Friedreich's ataxia treatment BMC Neurol 8 2008 20 10.1186/1471-2377-8-20
11. P. González-Cabo, R.P. Vázquez-Manrique, M.A. García-Gimeno, P. Sanz, and F. Palau Frataxin interacts functionally with mitochondrial electron transport chain proteins Hum Mol Genet 14 15 2005 2091 2098 10.1093/hmg/ddi214
12. M.D. Hebert Targeting the gene in Friedreich ataxia Biochimie 90 8 2008 1131 1139 10.1016/j.biochi.2007.12.005
13. D. Herman, K. Jenssen, R. Burnett, E. Soragni, S.L. Perlman, and J.M. Gottesfeld Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia Nat Chem Biol 2 10 2006 551 558 10.1038/nchembio815
14. J.D. Hayes, M. McMahon, S. Chowdhry, and A.T. Dinkova-Kostova Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway Antioxid Redox Signal 13 2010 1713 1748
15. T. Honda, H. Yoshizawa, C. Sundararajan, E. David, M.J. Lajoie, F.G. Favaloro Jr., and et al. Tricyclic compounds containing non-enolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents J Med Chem 54 2011 1762 1778
16. J. Jones, A. Estirado, C. Redondo, C. Bueno, and S. Martínez Human adipose stem cellconditioned medium increases survival of Friedreich's ataxia cells submitted to oxidative stress Stem Cells Dev 21 15 2012 2817 2826 10.1089/scd.2012.0029
17. V. Libri, C. Yandim, S. Athanasopoulos, N. Loyse, T. Natisvili, P.P. Law, and et al. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study Lancet 384 August (9942) 2014 504 513 10.1016/S0140-6736(14)60382-2 Epub 2014 Apr 30
18. C. Mariotti, W. Nachbauer, M. Panzeri, W. Poewe, F. Taroni, and S. Boesch Erythropoietin in Friedreich ataxia J Neurochem 126 Suppl. 1 2013 80 87 10.1111/jnc.12301. Review
19. A. Martelli, M. Napierala, and H. Puccio Understanding the genetic and molecular pathogenesis of Friedreich's ataxia through animal and cellular models Dis Models Mech 5 2 2012 165 176 10.1242/dmm.008706
20. C.J. Miranda, M.M. Santos, K. Ohshima, J. Smith, L. Li, M. Bunting, M. Cossée, M Koenig, J. Sequeiros, J. Kaplan, and M. Pandolfo Frataxin knockin mouse FEBS Lett. 13 512 1-3 2002 291 297
21. O. Kakhlon, H. Manning, W. Breuer, N. Melamed-Book, C. Lu, G. Cortopassi, and et al. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation Blood 112 13 2008 5219 5227 10.1182/blood-2008-06-161919
22. A.H. Koeppen, and J.E. Mazurkiewicz Friedreich ataxia: neuropathology revised J Neuropathol Exp Neurol 72 2 2013 78 90
23. M. Pandolfo Friedreich ataxia: the clinical picture J Neurol 256 Suppl. 3-8 2009 10.1007/s00415-009-1002-3
24. M. Pandolfo, J. Arpa, M.B. Delatycki, K.H. Le Quan Sang, C. Mariotti, A. Munnich, I. Sanz-Gallego, G. Tai, M.A. Tarnopolsky, F. Taroni, M. Spino, and F. Tricta Deferiprone in Friedreich's ataxia: a 6-month randomized controlled trial Ann. Neurol. 76 4 2014 509 521 10.1002/ana.24248
25. M.H. Parkinson, S. Boesch, W. Nachbauer, C. Mariotti, and P. Giunti Clinical features of Friedreich's ataxia: classical and atypical phenotypes J Neurochem 126 August (Suppl. 1) 2013 103 117 10.1111/jnc.12317
26. M. Perdomini, B. Belbellaa, L. Monassier, L. Reutenauer, N. Messaddeq, N. Cartier, and et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia Nat Med 20 May (5) 2014 542 547 10.1038/nm.3510 Epub 2014 Apr 6
27. S.L. Perlman A review of Friedreich ataxia clinical trial results J Child Neurol 27 9 2012 1217 1222 10.1177/0883073812453872
28. M.A. Pook, S. Al-Mahdawi, C.J. Carroll, M. Cossée, H. Puccio, L. Lawrence, and et al. Rescue of the Friedreich's ataxia knockout mouse by human YAC transgenesis Neurogenetics 3 October (4) 2001 185 193
29. T.E. Richardson, A.E. Yu, Y. Wen, S.-H. Yang, and J.W. Simpkins Estrogen prevents oxidative damage to the mitochondria in Friedreich's ataxia skin fibroblasts PLoS ONE 7 4 2012 e34600 10.1371/journal.pone.0034600
30. C. Sandi, M. Sandi, H. Jassal, V. Ezzatizadeh, S. Anjomani-Virmouni, S. Al-Mahdawi, and et al. Generation and characterisation of Friedreich ataxia YG8R mouse fibroblast and neural stem cell models PLOS ONE 9 February (2) 2014 e89488 10.1371/journal.pone.0089488
31. J.B. Schulz, and M. Pandolfo 150 years of Friedreich ataxia: from its discovery to therapy J Neurochem 126 August (Suppl. 1) 2013 1 3
32. Y. Shan, R.A. Schoenfeld, G. Hayashi, E. Napoli, T. Akiyama, M. Iodi Carstens, and et al. Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich's ataxia YG8R mouse model Antioxid Redox Signal 2013 10.1089/ars.2012.4537
33. M.S. Shchepinov, V.P. Chou, E. Pollock, J.W. Langston, C.R. Cantor, R.J. Molinari, and et al. Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease Toxicol Lett 207 November (2) 2011 97 103 10.1016/j
34. E. Soragni, W. Miao, M. Iudicello, D. Jacoby, S. De Mercanti, M. Clerico, and et al. Epigenetic therapy for Friedreich ataxia Ann Neurol 76 October (4) 2014 489 508 10.1002/ana.24260 Epub 2014 Sep 16
35. P. Vankan Prevalence gradients of Friedreich's ataxia and R1b haplotype in Europe co-localize, suggesting a common Palaeolithic origin in the Franco-Cantabrian ice age refuge J Neurochem 126 August (Suppl. 1) 2013 11 20 10.1111/jnc.12215
36. D. Velasco-Sánchez, A. Aracil, R. Montero, A. Mas, L. Jiménez, M. O'Callaghan, and et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia Cerebellum (London, England) 10 1 2011 1 8 10.1007/s12311-010-0212-7
37. R.B. Wilson Therapeutic developments in Friedreich ataxia J Child Neurol 27 9 2012 1212 1216 10.1177/0883073812449691